

**The Board of Directors**  
**Shanghai Fosun New Medicine Research Company Limited (上海復星新藥研究股份有限公司) (the “Offeror”)**

**The Board of Directors**  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司)**  
**(“Fosun Pharma”)**  
Building A  
No. 1289 Yishan Road  
Shanghai, 200233, China

December 23, 2024

Dear Sirs,

**Proposed privatisation of Shanghai Henlius Biotech, Inc. (stock code: 02696) (the “Company”) by the Offeror by way of merger by absorption of the Company and withdrawal of listing of the H shares of the Company**

We, Fosun International Capital Limited, refer to the composite document dated December 23, 2024 jointly issued by the Offeror, Fosun Pharma and the Company in relation to the captioned matter (the “**Composite Document**”). Unless otherwise defined herein, terms used in this letter shall have the same meanings as defined in the Composite Document.


We hereby give, and confirm that we have not withdrawn, our written consent to the issue of the Composite Document with the references to our name and logo in the form and context in which they respectively appear in the Composite Document.

We hereby confirm that we have given and have not withdrawn our consent to a copy of this consent letter being made available for inspection as described in the section headed “11. Documents on Display” in Appendix IV to the Composite Document.

*[The remainder of this page is deliberately left blank]*

Yours faithfully

For and on behalf of  
**FOSUN INTERNATIONAL CAPITAL LIMITED**

A handwritten signature in black ink, consisting of several overlapping loops and a trailing flourish, positioned above a horizontal line.

---

Name: Donald Chung  
Title: Head of Corporate Finance